Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Document › Details

4-Antibody AG. (10/8/12). "Press Release: 4-Antibody AG Receives Additional Milestone Payments from Human Genome Sciences". Basel.

Organisations Organisation 4-Antibody AG
  Group Agenus (Group)
  Organisation 2 Human Genome Sciences Inc. (Nasdaq: HGSI)
  Group GlaxoSmithKline (GSK) (Group)
Products Product therapeutic antibody
  Product 2 Retrocyte Display® technology
Index term Index term Human Genome Sciences–4-Antibody: Retrocyte Display technology, 201108– collab use to discover + develop fully human therapeutic antibodies
Person Person Burns, Robert F. (4-Antibody 201101– CEO before Affitech CEO before Celldex Therapeutics CEO)

4-Antibody AG today announced two additional milestone payments from the company's collaboration with Human Genome Sciences (HGS) to discover and develop fully human therapeutic antibodies. Specific details of the payments, which were made prior to completion of HGS' recent acquisition by GlaxoSmithKline plc, were not disclosed.

The collaboration with HGS began in August 2011 and focused on applying 4-Antibody's proprietary, high throughput, in vitro Retrocyte Display® technology (Retroviral B lymphocyteDisplay) for the rapid discovery of fully human antibodies against novel HGS targets. The Retrocyte Display technology is a potent tool for high quality therapeutic antibody discovery using a rapid flow cytometry approach. Full-length immunoglobulin antibody libraries are expressed in mammalian B-lineage cells, the cell designed by nature for optimal antibody display, resulting in 'better-behaved', fully human antibodies.

Dr Robert Burns, 4-Antibody's CEO, said: "The way in which the HGS collaboration progressed demonstrates 4-Antibody's ability to use its technology platform to generate high quality leads direct from screening. Companies which are target rich are key collaborators for us as they allow us to put the Retrocyte Display platform to work in multi-target projects. At the same time, we will continue to seek out service deals around our technology which will provide access to our platform to the wider market through our recently established partnership with Evotec."

Contact us

4-Antibody AG
Hochbergerstrasse 60C
CH-4057 Basel
T +41 (0)61 633 22 60
F +41 (0)61 633 22 61

Affiliate Germany
Winzerlaer Strasse 2
D-07745 Jena
T +49 (0)3641 508 230
F +49 (0)3641 508 113

Record changed: 2017-04-02


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Agenus (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [iito] Made Without Love 650x80px

» top